Supernus to Present at Cowen and Company Healthcare Conference in March

  Supernus to Present at Cowen and Company Healthcare Conference in March  Cowen and Company 34th Annual Healthcare Conference  Business Wire  ROCKVILLE, Md. -- February 20, 2014  Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will provide a business update on the Company at the Cowen and Company Healthcare Conference.                                   Presentation Date: Monday, March 3                       Time: 1:30pm ET                       Place: The Boston Marriott Copley Place Hotel, Boston,                       MA                         About Supernus Pharmaceuticals, Inc.  Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.  Contact:  Supernus Pharmaceuticals, Inc. Jack A. Khattar, President and CEO or Gregory S. Patrick, Vice President and CFO 301-838-2591 or Investor Contact: Cockrell Group, 877-889-1972 investorrelations@thecockrellgroup.com cockrellgroup.com